Prophylactic treatment of migraine with β-blockers and riboflavin: Differential effects on the intensity dependence of auditory evoked cortical potentials

Headache

Volumn 40, Issue 1, 2000, Pages 30-35

  Sándor, Peter S ^a   Áfra, Judit ^a   Ambrosini, Anna ^c   Schoenen, Jean ^b  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c NONE

Author keywords

Auditory evoked cortical potentials; Beta blockers; Intensity dependence; Migraine; Prophylactic treatment; Riboflavin

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; METOPROLOL; RIBOFLAVIN;

ADULT; ARTICLE; BRAIN CORTEX; BRAIN MITOCHONDRION; CLINICAL ARTICLE; CONTROLLED STUDY; ENERGY; EVOKED AUDITORY RESPONSE; FEMALE; HUMAN; INFORMATION PROCESSING; MALE; MIGRAINE; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; EVOKED POTENTIALS, AUDITORY; FEMALE; HUMANS; MALE; MENTAL PROCESSES; MIGRAINE DISORDERS; RIBOFLAVIN;

EID: 0342545925     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.2000.00005.x     Document Type: Article

References (20)

1. Proietti Cecchini A, Áfra J, Schoenen J. Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of CNS serotonin transmission in man: demonstration of a central effect for the 5-HT1B/1D agonist zolmitriptan (311C90, Zomig®). Cephalalgia. 1997;17:849-854.
2. Schoenen J. Pathogenesis of migraine: the biobehavioural and hypoxia theories reconciled. Acta Neurol Belg. 1994;94:79-86.
3. Wang W, Timsit-Berthier M, Schoenen J. Intensity dependence of auditory evoked potentials is pronounced in migraine: an indication of cortical potentiation and low serotonergic neurotransmission? Neurology. 1996;46:1404-1409.
4. Áfra J, Proietti Cecchini A, De Pasqua V, Albert A, Schoenen J. Visual evoked potentials during long-lasting pattern-reversal stimulations in migraine. Brain. 1998;121:233-241.
5. Welch KMA, Levine SR, D'Andrea G, et al. Preliminary observations on brain energy metabolism in migraine studied by in vivo 31-phosphorus NMR spectroscopy. Neurology. 1989;39:538-541.
6. Barbiroli B, Montagna P, Cortelli P, et al. Abnormal brain and muscle energy metabolism shown by 31P magnetic resonance spectroscopy in patients affected by migraine with aura. Neurology. 1992;42:1209-1214.
7. Montagna P, Cortelli P, Monari L, et al. 31P-Magnetic resonance spectroscopy in migraine without aura. Neurology. 1994;44:666-668.
8. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial. Neurology. 1998;50:466-470.
9. International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-96.
10. Schoenen J. Cortical electrophysiology in migraine and possible pathogenetic implications. Clin Neurosci. 1998;5:10-17.
11. Schoenen J. Beta-blockers and the central nervous system. Cephalalgia. 1986; 6(suppl 5):47-54.
12. Hegerl U, Juckel G. Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: a new hypothesis. Biol Psychiatry. 1993;33:173-187.
13. Lazarova-Bakarova MB, Stancheva S, Petkova B, et al. Effects of α-adrenoceptor blocker pindolol, calcium antagonist verapamil and their combination of retention in step-down and shuttle-box-trained rats and on brain biogenic monoamines. J Physiol Paris. 1997;91:301-305.
14. McAinsh J, Cruickshank JM. Beta-blockers and central nervous system side effects. Pharmacol Ther. 1990;46:163-167.
15. Dahlöf C, Dimenäs E. Side effects of beta-blockade treatment as related to the central nervous system. Am J Med Sci. 1990;299:236-244.
16. Penn AMW, Lee JWK, Thuillier P, et al. MELAS syndrome with mitochondrial tRNALeu(UUR) mutation: correlation of clinical state, nerve conduction, and muscle 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin. Neurology. 1992;42:2147-2152.
17. Antozzi D, Garavaglia B, Mora M, et al. Late-onset riboflavin responsive myopathy with combined multiple acyl coenzyme: a dehydrogenase and respiratory chain deficiency. Neurology. 1994;44:2153-2158.
18. Scholte HR, Busch HF, Bakker HD, Bogaard JM, Luyt-Houwen IE, Kuyt LP. Riboflavin-responsive complex I deficiency. Biochim Biophys Acta. 1995; 1271:75-83.
19. Gregersen N. Riboflavin-responsive defects of α-oxidation. J Inherit Metab Dis. 1985;8(suppl1):65-69.
20. Ferrari MD. Migraine. Lancet. 1998;351:1043-1051.